Literature DB >> 35841528

RhoGDI1 interacts with PHLDA2, suppresses the proliferation, migration, and invasion of trophoblast cells, and participates in the pathogenesis of preeclampsia.

Guiyu Song1, Feng Jin2.   

Abstract

Preeclampsia (PE) is a pregnancy-associated disease, which is the major cause of mortality on maternity and perinatal infants. It is hypothesized that PE is a consequence of the dysfunction of the trophoblast cells. Pleckstrin homology-like domain, family A, member 2 (PHLDA2) was shown to inhibit the proliferation, migration, and invasion of trophoblast cells in our previous studies. However, the mechanism by which PHLDA2 affects trophoblast cell function has not been clarified. In the current study, co-immunoprecipitation (Co-IP) with mass spectroscopy analysis was used to explore the proteins that interacted with PHLDA2. A total of 291 candidate proteins were found to be associated with PHLDA2. The interaction between PHLDA2 and Rho guanine nucleotide dissociation inhibitor (RhoGDI) 1 was identified by Co-IP and immunofluorescence staining. Western blot analysis indicated that overexpression of PHLDA2 resulted in upregulation of the RhoGDI1 protein levels, which were stabilized in the presence of cycloheximide. Similarly, overexpression of RhoGDI1 promoted PHLDA2 expression and its stability. Furthermore, pull-down and Co-IP results indicated that PHLDA2 repressed the activity of Rho guanosine triphosphate hydrolase family proteins by regulating RhoGDI1 expression. In addition, RhoGDI1 expression was upregulated in the placental tissues of patients with PE. The effects of the suppression of PHLDA2 expression on proliferation, migration, and invasion of trophoblast cells were partly abrogated following knockdown of RhoGDI1. Taken together, the data indicated that RhoGDI1 mediated regulation of PHLDA2 on the biological behavior of trophoblast cells and may participate in the pathophysiology of PE.
© 2022. The Author(s) under exclusive licence to Japan Human Cell Society.

Entities:  

Keywords:  PHLDA2; Preeclampsia; Rho GTPase; RhoGDI1; Trophoblast cell

Mesh:

Substances:

Year:  2022        PMID: 35841528     DOI: 10.1007/s13577-022-00746-w

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.374


  32 in total

1.  Global expression analysis identified a preferentially nerve growth factor-induced transcriptional program regulated by sustained mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) and AP-1 protein activation during PC12 cell differentiation.

Authors:  Steven Mullenbrock; Janki Shah; Geoffrey M Cooper
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

2.  The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP.

Authors:  A L Tranquilli; G Dekker; L Magee; J Roberts; B M Sibai; W Steyn; G G Zeeman; M A Brown
Journal:  Pregnancy Hypertens       Date:  2014-02-15       Impact factor: 2.899

Review 3.  Preeclampsia: Pathophysiology, Challenges, and Perspectives

Authors:  Sarosh Rana; Elizabeth Lemoine; Joey P Granger; S Ananth Karumanchi
Journal:  Circ Res       Date:  2019-03-29       Impact factor: 17.367

Review 4.  Preeclampsia: A review of the pathogenesis and possible management strategies based on its pathophysiological derangements.

Authors:  Amel A F El-Sayed
Journal:  Taiwan J Obstet Gynecol       Date:  2017-10       Impact factor: 1.705

5.  Identification of the human PHLDA1/TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation.

Authors:  Rüdiger Neef; Martina A Kuske; Elma Pröls; Judith P Johnson
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

6.  Perinatal outcome in singleton pregnancies complicated with preeclampsia and eclampsia in Ecuador.

Authors:  K Y N Phoa; P Chedraui; F R Pérez-López; J F Wendte; S Ghiabi; T Vrijkotte; P Pinto
Journal:  J Obstet Gynaecol       Date:  2016-01-20       Impact factor: 1.246

Review 7.  WITHDRAWN: Antiplatelet agents for preventing and treating pre-eclampsia.

Authors:  M Knight; L Duley; D J Henderson-Smart; J F King
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

Review 8.  The global impact of pre-eclampsia and eclampsia.

Authors:  Lelia Duley
Journal:  Semin Perinatol       Date:  2009-06       Impact factor: 3.300

9.  Keratinocyte growth factor induces gene expression signature associated with suppression of malignant phenotype of cutaneous squamous carcinoma cells.

Authors:  Mervi Toriseva; Risto Ala-aho; Sirkku Peltonen; Juha Peltonen; Reidar Grénman; Veli-Matti Kähäri
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

Review 10.  Syncytiotrophoblast-Derived Extracellular Vesicles in Pathophysiology of Preeclampsia.

Authors:  Cha Han; Lulu Han; Pengzhu Huang; Yuanyuan Chen; Yingmei Wang; Fengxia Xue
Journal:  Front Physiol       Date:  2019-10-01       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.